Q4 Earnings Forecast for Cingulate Issued By HC Wainwright
Equities research analysts at HC Wainwright issued their Q4 2024 EPS estimates for shares of Cingulate in a report issued on ...
Hosted on MSN13h
HC Wainwright & Co. Initiates Coverage of CRISPR Therapeutics (CRSP) with Buy Recommendation
Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...
H.C. Wainwright Raises BlackSky Technology Inc. (BKSY) Price Target to $20, Maintains ‘Buy’ Amid Strong Contract Growth
We recently compiled a list of the 10 Trending AI Stocks That Analysts Are Monitoring. In this article, we are going to take ...
bovnews16h
The BBAI Conundrum: Why BigBear.ai Holdings Inc’s Stock Is Making Headlines Again
H.C. Wainwright has recently reiterated BigBear.ai Holdings Inc (BBAI) stock to Buy rating, as announced on December 30, 2024, according to Finviz. Earlier, on January 9, 2024, Cantor Fitzgerald had ...
Knightscope, Inc. (KSCP) Receives ‘Buy’ Rating from H.C. Wainwright with $16 Target
We recently compiled a list of the 10 Trending AI Stocks on Wall Street’s Radar. In this article, we are going to take a look ...
Crispr Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...
Xoma price target lowered to $104 from $123 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Xoma (XOMA) to $104 from $123 and keeps a Buy rating on the shares. The firm removed ...